$KYMR News

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120

Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135

Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140

RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115

Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)

Kymera: Building Toward A Defining 2H26 Moment

B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125

Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136

B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155

Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129

BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target

Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis

Kymera Therapeutics Appoints Felix J. Baker Board Chairman, Succeeding Bruce Booth

Kymera Therapeutics Announces Results From Its Phase 1 Study Of KT-621 In Healthy Japanese Adults Were Shared At The Japanese Dermatological Association Annual Meeting, June 11-14

Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients

Kymera Therapeutics Presents New Preclinical Data For KT-579, Selective, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity In Lupus Models, At EULAR And FOCIS Congresses